Menu

Archives: Publications

A variability in response of osteoclasts to zoledronic acid is mediated by smoking associated modifcation in the DNA methylome
Qihua Tan, Anaïs Marie Julie Møller, Chuan Qiu, Jonna Skov Madsen, Hui Shen, Troels Bechmann, Jean-Marie Delaisse, Bjarne Winther Kristensen, Hong-Wen Deng, David Karasik & Kent Søe A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification...
Read More
The genetic overlap between osteoporosis and craniosynostosis
Erika Kague1*, Carolina Medina-Gomez2, Simeon A. Boyadjiev3 and Fernando Rivadeneira4 Published Sep 2022 https://doi.org/10.3389/fendo.2022.1020821 Osteoporosis is the most prevalent bone condition in the ageing population. This systemic disease is characterized by microarchitectural deterioration of...
Read More
High Bone Mass Disorders: New Insights from Connecting the Clinic and the Bench
Dylan J.M. Bergen PhD,Antonio Maurizi PhD,Melissa M. Formosa PhD,Georgina L.K. McDonald MSc,Ahmed El-Gazzar PhD,Neelam Hassan MD PhD,Maria-Luisa Brandi MD PhD,José A. Riancho MD PhD,Fernando Rivadeneira MD PhD,Evangelia Ntzani MD PhD,Emma...
View Newsletter
Read More
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
Anaïs M J Møller, Jean-Marie Delaisse, Jacob B Olesen, Troels Bechmann, Jonna S Madsen, Kent Søe First published: 15 September 2020DOI: https://doi.org/10.1002/jbm4.10412 Zoledronic acid is a bisphosphonate commonly used to treat...
Read More
Deletion of SREBF1, a Functional Bone-Muscle Pleiotropic Gene, Alters Bone Density and Lipid Signaling in Zebrafish
Chen Shochat, Zhiying Wang, Chenglin Mo, Sarah Nelson, Rajashekar Donaka, Jian Huang, David Karasik, Marco BrottoEndocrinology, Volume 162, Issue 1, January 2021, bqaa189, https://doi.org/10.1210/endocr/bqaa189Published: 17 October 2020 Through a genome-wide analysis of bone mineral density (BMD) and muscle mass,...
Read More
Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models
Erika Kague 1, David Karasik 2,*
Read More
Regenerating zebrafish scales express a subset of evolutionary conserved genes involved in human skeletal disease
Bergen et al, 21 January 2022
Read More
Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques
Martina Rauner et al, 30 November 2021 
Read More
Bone phenotyping approaches in human, mice and zebrafish – expert overview of the EU Cost Action GEMSTONE (“Genomics of MusculoSkeletal traits Translational Network”)
Ines Foessl et al, Nov. 2021
Read More
The "GEnomics of Musculo Skeletal Traits TranslatiOnal NEtwork": Origins, Rationale, Organization, and Prospects
Koromani F et al., Front. Endocrinol., 16 August 2021
Read More

COST Action CA18139

The musculoskeletal system is a key element for healthy aging, being mobility a fundamental component of quality of life, health, and independence of aging individuals. The unprecedented amount of discoveries arising from  genome-wide association studies (GWAS) have set a new era full of translational potential in the field of musculoskeletal biology.

Connect with us

Have a question? Send us an email to info@cost-gemstone.eu.
Sign up for GEMSTONE articles and resources:

COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation. See more at www.cost.eu.

Follow Us
Twitter Linkedin-in

© 2019-2023 GEMSTONE All rights reserved

Privacy Policy
Design by Boutik